Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data
AA Connor, S Gallinger - Nature Reviews Cancer, 2022 - nature.com
Pancreatic ductal adenocarcinoma (PDAC), already among the deadliest epithelial
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …
[HTML][HTML] Integrative considerations during the COVID-19 pandemic
COVID-19. Notwithstanding, this is an opportune time to be proactive. Using available in-
vitro evidence, an understanding of the virulence of COVID-19, as well as data from similar …
vitro evidence, an understanding of the virulence of COVID-19, as well as data from similar …
Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy
Intratumoral immune cells are crucial for tumor control and antitumor responses during
immunotherapy. Immune cell trafficking into tumors is mediated by binding of specific …
immunotherapy. Immune cell trafficking into tumors is mediated by binding of specific …
NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity
T cell–directed cancer immunotherapy often fails to generate lasting tumor control.
Harnessing additional effectors of the immune response against tumors may strengthen the …
Harnessing additional effectors of the immune response against tumors may strengthen the …
FLASH X-ray spares intestinal crypts from pyroptosis initiated by cGAS-STING activation upon radioimmunotherapy
X Shi, Y Yang, W Zhang, J Wang… - Proceedings of the …, 2022 - National Acad Sciences
DNA-damaging treatments such as radiotherapy (RT) have become promising to improve
the efficacy of immune checkpoint inhibitors by enhancing tumor immunogenicity. However …
the efficacy of immune checkpoint inhibitors by enhancing tumor immunogenicity. However …
Targeting the Siglec–Sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma
Glioblastoma (GBM) is the most aggressive form of primary brain tumor, for which effective
therapies are urgently needed. Cancer cells are capable of evading clearance by …
therapies are urgently needed. Cancer cells are capable of evading clearance by …
BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti‐PD‐1/PD‐L1 Immunotherapy by Negatively Regulating Proinflammatory …
Z Cai, J Chen, Z Yu, H Li, Z Liu, D Deng, J Liu… - Advanced …, 2023 - Wiley Online Library
To improve response rate of monotherapy of immune checkpoint blockade (ICB), it is
necessary to find an emerging target in combination therapy. Through analyzing tumor …
necessary to find an emerging target in combination therapy. Through analyzing tumor …
PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy
N Zhang, Y Gao, Z Huang, P Dai, Y Luo, Q Wu, X Jiang… - Cancer Letters, 2022 - Elsevier
Small cell lung cancer (SCLC) is a highly malignant tumor with extremely poor prognosis.
The treatment strategy is very limited, and patient outcomes remain dismal with the 5-year …
The treatment strategy is very limited, and patient outcomes remain dismal with the 5-year …
[HTML][HTML] Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma
Z Cai, Y He, Z Yu, J Hu, Z Xiao, X Zu, Z Li… - Frontiers in …, 2022 - frontiersin.org
Background Due to the different infiltration abundance of immune cells in tumor, the efficacy
of immunotherapy varies widely among individuals. Recently, growing evidence suggested …
of immunotherapy varies widely among individuals. Recently, growing evidence suggested …
Tissue-resident memory t cells in pancreatic ductal adenocarcinoma coexpress PD-1 and TIGIT and functional inhibition is reversible by dual antibody blockade
Pancreatic ductal adenocarcinoma (PDAC) has a poor clinical outlook. Responses to
immune checkpoint blockade are suboptimal and a much more detailed understanding of …
immune checkpoint blockade are suboptimal and a much more detailed understanding of …